Lesen Sie hier weiter... |  Drucken |  PDF

Ähnliche Artikel

• New Study Shows ENBREL(R) (etanercept) Is More Effective than a DMARD in the Treatment of Symptoms of Ankylosing Spondylitis Patients
• Dosing for RVX-208 Phase 1a Clinical Study Completed
• New Study Demonstrates That Lack of Pandemic Planning Will Affect Bottom Line
• Recent Research Shows Significant Benefits in Acute Ischaemic Stroke With Actilyse(R) Beyond Currently Approved Three Hour Treatment Window
• CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study
• Sanofi Aventis : New Study Results Support the"Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes
• ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
• Landmark UPLIFT Study Reaffirms the Safety of Spiriva (tiotropium) in Patients With Chronic Obstructive Pulmonary Disease
• Making a Real Difference to the Lives of Asthma Patients
• New Data Shows Pramipexole (Mirapexin(R)/Sifrol(R)) Can Significantly Reduce Limb Pain in Patients With Restless Legs Syndrome (RLS)

ots.at: das APA-OTS-Portal für multimediale Presseaussendungen

Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First 'Real.World, All Comers' Clinical Study = 01.09.2008 / 12:37

Presseportal: Biosensors International - Drug-Eluting Stent-Technologie ...

12:36 Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First 'Real World, All Comers' Clinical Study

FTOR - Finance-Community

Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First 'Real World, All Comers' Clinical Study

PRA International spricht während des europäischen Kongresses ...

Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First'Real World, All Comers' Clinical Study

Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry ...

Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First 'Real World, All Comers' Clinical Study